<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1974">
  <stage>Registered</stage>
  <submitdate>14/04/2008</submitdate>
  <approvaldate>14/04/2008</approvaldate>
  <nctid>NCT00680485</nctid>
  <trial_identification>
    <studytitle>Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416</studytitle>
    <scientifictitle>A Three Part Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeat Escalating Oral Doses of GSK580416; the Safety, Tolerability, and Pharmacokinetics of GSK580416 Following a Loading Dose Regimen; and the Effect of Ketoconazole on the Pharmacokinetics of GSK580416</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>OPS108221</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bacterial Infection</healthcondition>
    <healthcondition>Infections, Bacterial</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)

Treatment: drugs: GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of GSK580416 as determined by AUC, Cmax, tmax, half-life, and Ct.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy adults (as determined by medical evaluation including history, physical exam,
             vital signs, laboratory tests, and cardiac monitoring)

          -  Aged 18-60yrs, with BMI of 19-31kg/m2.

          -  Females must be of non-childbearing potential.

          -  QTc &lt; 450 msec at screening.

          -  Subjects must be able to give consent and comply with restrictions of study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>64</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic or GI
             condition or history that may place the subject at an unacceptable risk or may
             interfere with absorption, distribution, metabolism, or excretion of drug.

          -  Positive urine drug screen.

          -  Positive urine test for alcohol.

          -  Positive HIV or Hep B and/or C assay.

          -  History of regular tobacco use within 3 monts prior to screening or cotinine levels
             indicative of smoking at screening.

          -  History of regular alcohol consumption (14 units/week for women and 21 units/week for
             men).

          -  History of drug abuse or dependence within 12 months of study.

          -  Participation in another drug trial within 30 days of first dose.

          -  Exposure to more than 4 new chemical entities within 12 months of first dose.

          -  Use of prescription and non-prescription drugs including vitamins, dietary
             supplements, herbals within 7 days of first dose or St. John's Wort within 28 days of
             the first dose.

          -  Consumption of red wine, Seville oranges, grapefruit, or grapefruit juices within 14
             days of first dose.

          -  Donation of blood in excess of 500 mL within 56 days of dosing. No blood donation is
             allowed 30 days prior to study participation.

          -  A positive immunochemical fecal occult blood test at screening.

          -  History of sensitivity to any of the study medications.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  History of orthostatic hypotension or orthostatic hypotension at screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>GSK Investigational Site - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety, tolerability and exposure of repeat escalating oral
      doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with
      ketoconazole, a PGP/CYP3A4 inhibitor.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00680485</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>